Shanghai Haixin Biotechnology

Shanghai Haixin Biotechnology is a Chinese clinical-stage biopharmaceutical company and a subsidiary of the Shanghai Haixin Group, focusing on the development of innovative cancer immunotherapies. The company is a pioneer in the field of dendritic cell (DC) vaccines in China, with its lead candidate, APDC (Antigen Pulsed Dendritic Cells), currently in Phase III clinical trials for the treatment of metastatic colorectal cancer. APDC is a personalized autologous cell therapy that utilizes tumor lysates to sensitize dendritic cells, which are then re-administered to the patient to stimulate a targeted immune response. Haixin Biotechnology represents a core component of its parent group's "Great Health" strategy, aimed at establishing an integrated industry chain for oncology treatment. Despite encountering challenges in clinical trial enrollment due to its early protocol design, the company remains a significant player in the domestic cell and gene therapy landscape. Its work spans from early-stage research to the management of large-scale multi-center clinical trials across major hospitals in China.